Tier 2 — strong

Rapid Reduction of Pro-Inflammatory Cytokines with an Oral Topical Composition Comprising Olive Oil, Trimethylglycine and Xylitol: A Randomized Double-Blind Controlled Trial

José López-López, José M Reuss, Teresa Vinuesa-Aumedes, Sonia Egido-Moreno, Xavier Roselló-Llabres, Tanya Pereira-Riveros, Debora Reuss, Laura Alonso-Gamo, Beatriz Rodríguez-Vilaboa
International journal of molecular sciences 2025 26(10):4920

Bibliography

PubMed
PMID 40430061
PubMed Central
PMC12112298
DOI
10.3390/ijms26104920
Funding
Reported funding/support: There was no funding source for this study.
Competing interests
Reported disclosure: Beatriz Rodríguez-Vilaboa is founding member of Mucosa Innovations S.L. Mucosa Innovations is the owner and developer of technology specifically focused on mucosal cancer-therapy-related toxicities, microbiome modulation pathways and mucosa-related women’s health conditions. Mucosa Innovations S.L. is the owner of all intellectual property and technology (registered in the US Patent and Trademark Office (USPTO) and the European Patent Office (EPO)). Mucosa Innovations S.L. provided the study materials (toothpastes) tested in this clinical trial. All other authors declare no competing interests.

Study snapshot

DesignRandomized controlled trial
ModelHuman participants
Sample26 enrolled; 22 analyzed
InterventionOlive oil, trimethylglycine and xylitol toothpaste versus placebo, three times daily
Duration1 month
EndpointsSalivary cytokines; Local inflammation

What the study showed, in plain terms

Published in 2025, this source examined betaine hcl and topical formulations. Design: Randomized controlled trial. Sample/model: 26 enrolled; 22 analyzed. The exposure or intervention was Olive oil, trimethylglycine and xylitol toothpaste versus placebo, three times daily. Follow-up or treatment period: 1 month.

Selected salivary IL-1beta and TNF-alpha comparisons favored the test formula; IL-4 did not show a significant between-group difference.

Small multi-ingredient trial with subgroup and biomarker analyses. Salivary cytokine changes do not establish reduced systemic inflammation.

Continue with TMG Data Center

Continue with Betaine Anhydrous vs Betaine HCl: Which Form Is TMG?

Key findings

  • Selected salivary IL-1beta and TNF-alpha comparisons favored the test formula; IL-4 did not show a significant between-group difference.
  • The recorded outcome domains were Salivary cytokines; Local inflammation.
  • The result applies to the tested exposure: Olive oil, trimethylglycine and xylitol toothpaste versus placebo, three times daily; 1 month.

What this study can and cannot tell us

  • Small multi-ingredient trial with subgroup and biomarker analyses. Salivary cytokine changes do not establish reduced systemic inflammation.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Meal-Time Supplementation with Betaine HCl for Functional Hypochlorhydria: What is the Evidence?
Thomas G Guilliams et al. · Integrative medicine (Encinitas, Calif.) · 2020
Tier 2
Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria
Marc R Yago et al. · Molecular pharmaceutics · 2013
Tier 2
The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria
Marc R Yago et al. · The AAPS journal · 2014
Tier 2
Food, Acid Supplementation and Drug Absorption - a Complicated Gastric Mix: a Randomized Control Trial
Dalga D Surofchy et al. · Pharmaceutical research · 2019

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology